CORC

在结果中检索

CORC

浏览/检索结果: 共43条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Li, Ning;  Zhang, Youzhong;  Wang, Jing;  Zhu, Jianqing;  Wang, Li
收藏  |  浏览/下载：29/0  |  提交时间：2022/12/22
Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study 期刊论文
CLINICAL CANCER RESEARCH, 2022, 卷号: 28
作者:  Wu, Xiaohua;  Zhu, Jianqing;  Wang, Jing;  Lin, Zhongqiu;  Yin, Rutie
收藏  |  浏览/下载：103/0  |  提交时间：2022/03/28
High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer 期刊论文
BREAST CANCER, 2021
作者:  Zhu, Liang;  Pan, Jia-Ni;  Qian, Ziliang;  Ye, Wei-Wu;  Wang, Xiao-Jia
收藏  |  浏览/下载：23/0  |  提交时间：2021/09/06
CIN  TP53  BRCA1  LPWGS  Breast cancer  
Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2020, 卷号: 32, 期号: 3, 页码: 370-+
作者:  Li, Huiping;  Liu, Rongrui;  Shao, Bin;  Ran, Ran;  Song, Guohong
收藏  |  浏览/下载：22/0  |  提交时间：2020/12/24
Multiple cancer susceptible genes sequencing in BRCA-negative breast cancers with high hereditary risk 会议论文
作者:  Lang, G-T;  Hu, X.;  Shao, Z-M;  Huang, W.;  Shi, J-X
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial 期刊论文
2019, 卷号: 120, 页码: 20-30
作者:  Robson Mark;  Ruddy Kathryn J;  Im Seock-Ah;  Senkus Elżbieta;  Xu Binghe
收藏  |  浏览/下载：21/0  |  提交时间：2020/01/03
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer 期刊论文
2019, 卷号: 30, 期号: 4, 页码: 558-566
作者:  Robson, M. E.;  Tung, N.;  Conte, P.;  Im, S-A;  Senkus, E.
收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03
Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes 期刊论文
2019, 卷号: 8, 期号: 5, 页码: 2074-2084
作者:  Wang, Jiayu;  Li, Weiwei;  Shi, Yujian;  Huang, Yan;  Sun, Tao
收藏  |  浏览/下载：28/0  |  提交时间：2020/01/03
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文
作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A.
收藏  |  浏览/下载：12/0  |  提交时间：2019/12/05
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 期刊论文
CANCER RESEARCH, 2018, 卷号: 78, 期号: 4
作者:  Domchek, Susan M.;  Robson, Mark;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace